ER stress–mediated autophagy promotes Myc-dependent transformation and tumor growth

Lori S. Hart,1 John T. Cunningham,2 Tatini Datta,1 Souvik Dey,1 Feven Tameire,1 Stacey L. Lehman,1 Bo Qiu,1 Haiyan Zhang,1 George Cerniglia,1 Meixia Bi,1 Yan Li,2 Yan Gao,3 Huayi Liu,1 Changhong Li,4 Amit Matty,1 Andrei Thomas-Tikhonenko,5 Alexander E. Perl,6 Albert Koong,7 Serge Y. Fuchs,8 J. Alan Diehl,3 Ian G. Mills,9,10,11 Davide Ruggero,2 and Constantinos Koumenis1

1Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 2School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, UCSF, San Francisco, California, USA. 3Department of Cancer Biology and Abramson Family Cancer Research Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA. 4Department of Pediatrics and 5Department of Pathology and Laboratory Medicine, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. 6Division of Hematology/Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA. 7Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA. 8Department of Animal Biology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA. 9Prostate Cancer Research Group, Centre for Molecular Medicine Norway, University of Oslo, Oslo, Norway. 10Department of Urology, and 11Department of Cancer Prevention, Oslo University Hospitals, Oslo, Norway.

The proto-oncogene c-Myc paradoxically activates both proliferation and apoptosis. In the pathogenic state, c-Myc–induced apoptosis is bypassed via a critical, yet poorly understood escape mechanism that promotes cellular transformation and tumorigenesis. The accumulation of unfolded proteins in the ER initiates a cellular stress program termed the unfolded protein response (UPR) to support cell survival. Analysis of spontaneous mouse and human lymphomas demonstrated significantly higher levels of UPR activation compared with normal tissues. Using multiple genetic models, we demonstrated that c-Myc and N-Myc activated the PERK/eIF2α/ATF4 arm of the UPR, leading to increased cell survival via the induction of cytoprotective autophagy. Inhibition of PERK significantly reduced Myc-induced autophagy, colony formation, and tumor formation. Moreover, pharmacologic or genetic inhibition of autophagy resulted in increased Myc-dependent apoptosis. Mechanistically, we demonstrated an important link between Myc-dependent increases in protein synthesis and UPR activation. Specifically, by employing a mouse minute (L24+/–) mutant, which resulted in wild-type levels of protein synthesis and attenuation of Myc-induced lymphomagenesis, we showed that Myc-induced UPR activation was reversed. Our findings establish a role for UPR as an enhancer of c-Myc–induced transformation and suggest that UPR inhibition may be particularly effective against malignancies characterized by c-Myc overexpression.

Introduction

The unfolded protein response (UPR) is a cellular homeostatic program initiated by an excess of unfolded/misfolded client proteins in the ER lumen, with a primarily cytoprotective effect. There are 3 ER-resident proximal sensors of unfolded proteins and ER stress: PKR-like ER stress kinase (PERK), activating transcription factor 6 (ATF6), and inositol-requiring transmembrane kinase and endoribonuclease 1 (IRE1) (1–3). Under steady-state conditions, these stress sensors are bound by the chaperone protein GRP78 (BiP). The accumulation of unfolded proteins results in the dissociation of GRP78 and the subsequent activation of PERK, ATF6, and IRE1 (4, 5). Active PERK phosphorylates eukaryotic initiation factor 2-alpha (eIF2α) at Ser51, preventing the exchange of GDP for GTP, effectively blocking the initiation of protein synthesis during cellular recovery from ER stress (6). While general protein synthesis is limited, the translation of specific mRNAs is induced, including that of the transcription factor ATF4 (7). Stresses in the tumor microenvironment (e.g., low oxygen, decreased amino acid availability, and low glucose) activate components of the UPR, the abrogation of which leads to inhibition of tumor progression (8–13). In addition to microenvironmental stressors, the loss of tumor suppressor function, specifically of the tuberous sclerosis complex genes (TSC1, TSC2), has also been associated with UPR activation (14). Collectively, these findings reveal a link between UPR activation and adaptation to tumor microenvironmental stress.

Another cellular adaptation mechanism induced by both normal and transformed cells is autophagy, a self-digestive cellular stress response that enables cells to catabolize and recycle proteins, cytosolic components, and organelles to promote survival (15). Common cellular stresses known to induce autophagy include amino acid starvation, glucose withdrawal, and ER stress. The regulation of autophagy is accomplished primarily by the autophagy-related (Atg) proteins, organized into multiple complexes and acting at various stages within the pathway. Activation of a specific major complex (the ULK1 [Atg1] kinase complex) leads to a signaling cascade that culminates in the formation of the autophagosome, a double-membrane vesicle that encloses the cellular contents destined for degradation. Once fully formed, the autophagosomes fuse with lysosomes, resulting in the degradation and recycling of their contents. Although autophagy may play a complex role in tumorigenesis and tumor resistance to therapy (16–18), Atg proteins have been proposed as attractive targets for cancer therapy (18, 19). Cells under ER stress have been shown to
activate macro-autophagy, and it has been suggested that at least part of the autophagosomal membrane originates from enlarged ER membrane (20, 21) and is dependent on an active PERK/eIF2α pathway (22). Recently, it was shown that in response to hypoxic stress, PERK-dependent increases in ATF4 lead to prolonged autophagic flux, contributing to hypoxic adaptation (10).

Cell-autonomous insults, including oncogene activation, are known to activate cellular stress responses, including metabolic stress, apoptosis, DNA damage responses, and cellular senescence. Therefore, transformed cells often acquire a concurrent activation of pro-survival pathways (23–25). In particular, the MYC oncogene, which is the target of chromosomal translocation and gene amplification during the development of many human cancers, is known to induce both increased proliferation and apoptosis, depending on the cellular context (26–28). c-Myc functions as a transcription factor and induces proliferation through the upregulation of genes required for cell cycle progression (cyclin D, cyclin E), energy metabolism (lactate dehydrogenase A, GLUT1) (29), and ribosome biogenesis (RNA polymerase III, ribosomal proteins) (30). The latter has been associated with an increased rate of protein synthesis, which is required for MYC oncogenic activity and survival (31–33). However, the particular pathways under MYC-dependent translational control and the underlying mechanism by which this occurs remain elusive.

Based on the ability of the MYC oncogene to induce considerable increases in both ribosome biogenesis and rates of protein synthesis (reviewed extensively in refs. 34, 35), we hypothesized that oncogenic activation of c-Myc during transformation would inflict ER stress and elicit UPR activation. Moreover, we reasoned that such an induction of the UPR would be cytoprotective and thus promote MYC-dependent tumorigenesis. Using several inducible MYC cell models as well as genetic and pharmacologic tools, we show that MYC induction leads to activation of the PERK/eIF2α/ATF4 axis of the UPR, resulting in increased autophagy and protection against ER-dependent apoptosis. Moreover, we demonstrate that robust upregulation of the UPR occurs in human lymphoma samples and mouse lymphoma models, suggestive of a role for UPR activation in the pathogenesis of disease. Therefore, we have identified a cell-autonomous role for PERK as a molecular switch regulating autophagy and apoptosis in response to MYC activation, and have uncovered PERK as a therapeutic target for the treatment of MYC-associated malignancies.

**Results**

c-Myc activation initiates PERK-dependent UPR signaling that is attenuated by chemical chaperones. We hypothesized that c-Myc activation increases the protein load of the ER and activates cytoprotective UPR signaling. To test this, we employed two cell lines with regulated c-Myc expression: the human P493-6 B cell line, in which c-Myc expression is repressed in the presence of tetracycline (Tet-off c-Myc), and immortalized mouse embryonic fibroblasts (MEFs) stably expressing the tamoxifen-inducible c-Myc chimera mycER-P493-6 cells were cultured in the presence or absence of tetracycline, and UPR activation was analyzed by immunoblot analysis for eIF2α phosphorylated at serine 51 (p-eIF2α). In the absence of tetracycline, P493-6 cells expressed robust levels of c-Myc, which correlated with high levels of p-eIF2α (Figure 1A) and mRNA levels of the c-Myc target ornithine decarboxylase (ODC) (Supplemental Figure 1A; supplemental material available online with this article; doi:10.1172/JCI62973DS1). Addition of tetracycline resulted in rapid and nearly complete c-Myc downregulation within 4 hours, followed by a decrease in the levels of p-eIF2α by 24 hours, while total eIF2α levels remained unchanged. The delay between the loss of c-Myc expression and decreased p-eIF2α is likely due to the time required for recovery from the presence of unfolded proteins in the ER. When cells were cultured in tetracycline-free medium, c-Myc levels rebounded rapidly, which coincided with increased levels of p-eIF2α, ODC mRNA, and cell size (Figure 1A, Supplemental Figure 1, A and B, and ref. 31). When cells in which c-Myc was repressed (24-hour tetracycline treatment) were treated with the SERCA pump inhibitor and ER stress inducer thapsigargin, eIF2α phosphorylation was increased, demonstrating that cells lacking c-Myc expression maintain intact UPR signaling.

To further analyze UPR induction, we measured the nuclear accumulation of the downstream UPR target ATF4 (Figure 1B). As with p-eIF2α, the level of nuclear ATF4 correlated with c-Myc expression, indicative of UPR activation specifically through PERK. Spliced X-box binding protein–1 (XBP1s) transcript level was also reduced by 50% when c-Myc expression was inhibited (Figure 1C). Taken together, these results suggest that both the PERK and IRE1 arms of the UPR pathway are activated in human lymphoma cells in response to c-Myc upregulation. To test whether these findings extend to other MYC family members, we used two neuroblastoma cell lines with differentially regulated N-Myc: tamoxifen-inducible N-MycER activation in human neuroblastoma SHEP cells (36) and tetracycline-inducible N-Myc expression in Tet-21 SHEP cells (37). Activation of N-Myc caused upregulation of the UPR targets ATF4 and XBP1s in N-MycER SHEP cells (Figure 1D) and eIF2α phosphorylation in Tet-21 SHEP cells (Supplemental Figure 1C).

To test whether PERK is required for c-Myc–dependent UPR activation, we used SV40-immortalized MEFs from Perk−/− mice, in which the Perk gene is flanked by loxP sites, permitting Perk excision following infection with Ad-Cre, a Cre recombinase–expressing adenovirus. The MEFs were transduced with a retroviral vector expressing a mycER fusion protein to establish cells (mycER:Perk−/−) with tamoxifen-activated c-Myc. As expected, Myc activation resulted in a significant increase in protein synthesis (Supplemental Figure 2A). Similar to the UPR activation in human P493-6 cells, p-eIF2α and p-PERK levels were increased following treatment with the tamoxifen analog 4-hydroxytamoxifen (4-HT) (Figure 1E). Importantly, in the absence of PERK (mycER:Perk−/− clone 2.2, Supplemental Figure 3A), eIF2α phosphorylation was substantially attenuated, indicating that Myc-induced eIF2α phosphorylation is PERK dependent (Figure 1E). We also measured ATF4 activation using a reporter construct with luciferase expression under control of the 5′ UTR of ATF4 (38), which contains two open reading frames with opposing activity, one positive-acting and one inhibitory. Wek and colleagues demonstrated that under conditions of ER stress and eIF2α phosphorylation, delays in ribosomal scanning allow for successful translation from the positive-acting reading frame, resulting in increased ATF4 protein levels (39). ATF4 was induced in mycER:Perk−/− MEFs following either Myc or thapsigargin treatment; in contrast, the mycER:Perk−/− MEFs were deficient in ATF4 induction (Figure 1F). Collectively, these findings indicate that c-Myc activation is sufficient to activate ER stress and the PERK/eIF2α/ATF4 arm of the UPR. Unlike in P493-6 cells, we did not observe XBP1 splicing in MEFs upon Myc activation (Supplemental Figure 3B), suggesting that the IRE1/XBP1 arm of the UPR may be activated by c-Myc in a cell-specific or host-specific manner.

http://www.jci.org   Volume 122   Number 12   December 2012

Downloaded from http://www.jci.org on April 1, 2018.   https://doi.org/10.1172/JCI62973
To test whether c-Myc activates the UPR via the accumulation of unfolded or misfolded proteins, we co-treated mycER:Perk\textsuperscript{fl/f}\textsuperscript{l} MEFs with 4-HT and the chemical chaperone 4-phenylbutyric acid (4-PBA), which has been shown to augment protein folding and attenuate metabolic abnormalities and insulin resistance in a mouse model of diabetes (40). 4-PBA completely blocked c-Myc–induced UPR activation (Figure 1G) without significantly affecting c-Myc accumulation (Supplemental Figure 2B). As expected,
4-PBA also limited the phosphorylation of eIF2α induced by the glycosylation inhibitor and ER stress–inducing agent tunicamycin. These findings indicate that c-Myc–induced UPR activation is overridden by increased chaperone activity.

To further test our hypothesis that c-Myc expression activates the UPR via the induction of ER stress, we examined the morphology of the ER. Activation of c-Myc by addition of 4-HT resulted in more prominent ER morphology than in vehicle-treated control cells (Figure 2A), corresponding to a significantly higher ER/nucleus ratio (Figure 2B) and a 3-fold increase in the fluorescence of the ER-specific probe ER-Tracker (Supplemental Figure 3C). Electron microscopy revealed a substantial increase in ER area, with clearly expanded membranes and distended lumen in mycER:Perkfl/fl cells following 16-hour treatment with 4-HT compared with control cells (Figure 2C). Moreover, flow cytometric analysis of ER-Tracker staining showed a 28% increase in ER fluorescence in human P493-6 cells with activated c-Myc (Supplemental Figure 3D). These findings implicate c-Myc in the morphological expansion of the ER, indicative of the accumulation of misfolded proteins and dysregulated ER function in the absence of PERK.

PERK-dependent UPR signaling promotes cell survival following c-Myc activation. Next, we investigated the cellular outcome of both PERK-proficient and PERK-deficient MEFs when challenged with c-Myc induction. PERK ablation dramatically decreased cell survival following c-Myc activation as measured by clonogenic growth assay (Figure 3A). Immunoblot analysis revealed the upregulation of cleaved poly ADP ribose polymerase (PARP) following Myc activation, which was substantially greater in the absence of PERK (Figure 3B), indicating that induction of apoptosis was contributing to decreased clonogenicity in PERK-deficient cells. Cell cycle analysis revealed a Myc-induced increase in the fraction of cells in S phase (decreased G1/S ratio) in both mycER:Perkfl/fl and mycER:Perk–/– cells (Supplemental Figure 2C). Results from examination of morphological changes with phase contrast microscopy and sub-G1 content further...
corroborated the induction of apoptosis in PERK-deficient cells (Supplemental Figure 4, A and B). Furthermore, treatment of PERK-deficient cells with the chemical chaperone 4-PBA reduced the cytotoxic effect of c-Myc activation (Figure 3C), suggesting that c-Myc-induced cell death in the absence of PERK is dependent upon the presence of misfolded proteins. In order to determine whether eIF2α phosphorylation and subsequent decreased translation are required for cell survival in PERK-proficient cells, we employed MEFs with an eIF2α S51A knock-in mutation rendering the protein incapable of phosphorylation, thereby preventing UPR-induced downregulation of translation. As in PERK-deficient cells, Myc activation in S51A eIF2α knock-in MEFs resulted in significantly more cell death relative to wild-type cells (Figure 3D and Supplemental Figure 4C).

To further characterize the c-Myc-induced apoptosis, we transiently overexpressed wild-type Bcl-xL or ER-targeted Bcl-xL-cb5 in mycER:Perk−/− MEFs and measured their response to Myc activation. Both wild-type Bcl-xL and ER-targeted Bcl-xL significantly rescued the PERK-deficient cells from Myc-induced apoptosis (Figure 3E and Supplemental Figure 4D). We also employed the pan-caspase inhibitory peptide Q-VD-OPH. The addition of Q-VD-OPH prevented c-Myc–induced PARP cleavage and rescued cell survival in mycER:Perk−/− MEFs treated with 4-HT and in cells treated with the proapoptotic agent staurosporine, whereas a negative control peptide had no cytoprotective effect (Supplemental Figure 4, E and F).

ER stress–induced apoptosis involves the release of intracellular Ca²⁺ from ER stores and subsequent cytochrome c release from
We measured intracellular Ca\(^{2+}\) release by fluorescence microscopy with the Fura-2AM dye and found a significant increase in free intracellular calcium in c-Myc-induced cell death. As expected, thapsigargin induced a more robust release of calcium. To further test whether the mechanism of cell death induced by c-Myc in the absence of PERK was ER stress dependent, we employed the calcium chelator BAPTA-AM to block the activity of released calcium. Whereas treatment of mycER::Perk\(^{–/–}\) MEFs with 4-HT resulted in the cleavage of PARP, the presence of BAPTA-AM significantly reduced PARP cleavage (Supplemental Figure 4H). Taken together, our results suggest that c-Myc induces the accumulation of misfolded proteins, which in the absence of PERK results in unmanageable ER stress, the subsequent release of calcium, and the initiation of caspase-dependent apoptosis.

**c-Myc induces PERK-dependent cytoprotective autophagy.** ER stress-induced autophagy was originally described in yeast, where activation of the UPR results in ER expansion and the formation of autophagosomes with ER-derived membranes (42). Moreover, UPR-induced activation of ATF4 has been shown to upregulate the autophagy genes ATG5 and MAP1LC3B to promote cell survival during acute hypoxic stress (10, 43). Additionally, autophagy has been shown to promote the survival of tumor cells in a mouse model of Myc-induced lymphomas (19). Therefore, we examined...
autophagy as a potential contributor to PERK-mediated cell survival. Electron microscopy revealed the presence of double-membrane vesicles, indicative of autophagosome formation in mycER:Perk^{f/f} MEFs treated with 4-HT (Figure 4A). The mycER:Perk^{+/+} MEFs lacked significant vesicle formation but demonstrated evidence of apoptosis, such as condensed chromatin in the nuclei. In addition to performing electron microscopy, we analyzed two markers of autophagy, p-eIF2α (S51) and p-Perk, in B lymphocytes from WT, myc-expressing transgenic mice, and myc-expressing murine HPCs. The presence of acidic vesicles associated with autophagy results in the processing of LC3I (into LC3II) and the rapid degradation of the p62 protein. Treatment with 4-HT induced apoptosis in HPCs from Perk^{f/f} CreER mice, as evidenced by Annexin V and 7-AAD staining (Figure 5).
with thapsigargin resulted in PERK-dependent upregulation of LC3II levels in the mycER MEFs (Supplemental Figure 5A). Similar to thapsigargin-induced ER stress, c-Myc expression resulted in increased LC3II processing by both static (Figure 4B) and flux (Supplemental Figure 5B) assays, which was attenuated in Perk−/− MEFs. Additionally, p62 was efficiently degraded in the presence of c-Myc in a PERK-dependent manner (Figure 4C). In mycER:Perk−/− MEFs, we reproducibly observed a marginal, but temporary decrease in p62 levels at 8 hours following 4-HT treatment, suggesting that unsustained autophagic flux is induced in the absence of PERK signaling, further corroborated by the flux assay measuring LC3II (Supplemental Figure 5B). Starvation-induced autophagy in the mycER:Perk−/− MEFs indicated that PERK-deficient cells are capable of inducing autophagy by means other than c-Myc expression. The degradation of p62 was dependent on the presence of misfolded proteins, as treatment of cells with 4-PBA rescued c-Myc–dependent p62 degradation (Figure 4D). c-Myc–induced autophagy was also apparent in P493-6 cells, as measured by LysoTracker staining (Supplemental Figure 5C). Collectively, these results indicate that autophagy is activated by c-Myc in a PERK-dependent manner.

To determine whether autophagy induction actively protects cells from c-Myc–induced apoptosis, we blocked autophagy in mycER:Perk−/− MEFs by treatment with bafilomycin A1 and measured cleaved PARP and p62 levels following induction of c-Myc expression. c-Myc–induced PARP cleavage was augmented in cells treated with bafilomycin A1, compared with vehicle-treated cells (Figure 4E). Increased cell death corresponds with increased p62, indicative of incomplete autophagy. We also observed a dose-dependent effect of bafilomycin A1 on PARP cleavage in response to Myc activation (Supplemental Figure 5D). Sputain-1, a specific autophagy inhibitor, promotes the degradation of the Vps34-Beclin1 complex and prevents the initiation of autophagy and elongation of the autophagosomal membrane (44). Sputain-1 treatment inhibited the accumulation of LC3III and, similar to bafilomycin A1 treatment, resulted in increased PARP cleavage in mycER:Perk−/− MEFs upon Myc activation (Supplemental Figure 5, E and F).

ULK1, a kinase involved in autophagy initiation, and Atg5, a member of the E3 ligase complex, are both required for complete autophagic flux (45, 46). To analyze the role of autophagy genetically, we measured cleaved PARP levels following induction of c-Myc expression in mycER:Perk−/− cells transfected with siRNA targeting ULK1 and in Atg5−/− and Atg5+/− MEFs infected with myc-ER-expressing virus. c-Myc–induced PARP cleavage was increased in the absence of ULK1 or Atg5, compared with non-targeting siRNA or Atg5−/− MEFs, respectively (Figure 4, F and G). In addition to increased apoptosis, clonogenic survival was significantly reduced in Atg5-deficient MEFs treated with 4-HT compared with Atg5-proficient cells (Supplemental Figure 5G). Collectively, these results indicate that autophagy is activated in a PERK-dependent manner and promotes cell survival during c-Myc–induced activation of the UPR in vitro.

Ribosomal L24 heterozygosity rescues c-Myc–induced PERK activation and autophagy in Eu-myc lymphocytes. To test our findings in a physiological model of lymphomagenesis, we examined lymphocytes from the spleens of Eu-myc and wild-type mice for activation of the UPR prior to tumor formation. The Eu-myc transgenic mouse is an important model for Myc-induced tumor development in vivo. In Eu-myc mice, c-Myc transgene expression is driven by the immunoglobulin transcriptional enhancer Eμ, and the mice develop B cell lymphomas and lymphoid leukemias (47), consistent with the fact that Myc is deregulated in 100% of Burkitt’s lymphoma in humans. Premalignant Eμ-myc lymphocytes from 5-week-old mice showed a substantial increase in UPR activation as measured by p-PERK, p-eIF2α, and XBP1s levels compared with wild-type littermate controls (Figure 5, B and C). We next assessed whether Myc-dependent increases in protein synthesis that augment the protein load of the ER may underlie UPR activation. We utilized a mouse mutant that lacks one copy of ribosomal protein L24 to restore Myc-dependent increases in protein synthesis to wild-type levels (ref. 32 and Figure 5A). Importantly, we have previously shown that ribosomal protein haptolinsufficiency markedly attenuates Eμ-myc–driven lymphoma (32). Splenic lymphocytes from Eμ-myc/+;L24+/− transgenic mice were analyzed for UPR activation prior to tumor formation (Figure 5, B and C) and were found to have near wild-type levels of p-PERK, p-eIF2α, and XBP1s. Additionally, the appearance of LC3II processing in lymphocytes from Eμ-myc mice confirms the induction of Myc-associated autophagy in vivo, which is prevented in double transgenic Eμ-myc/+;L24−/− mice (Figure 5D).

Ablation of PERK leads to apoptosis of Myc-transformed primary cells and inhibition of tumor growth in vivo. We examined the effects of PERK status on the growth of c-Myc–driven Perk−/− and Perk−/− MEFs in an allograft model. RasV12-transformed MEFs were injected subcutaneously in athymic mice, and the mice were treated with tamoxifen to induce c-Myc throughout the course of the experiment. Abrogation of PERK resulted in a nearly complete inhibition of c-Myc–dependent tumor growth (Figure 5E). These results strongly suggest that restraining the ability of c-Myc to increase protein synthesis (L24 heterozygosity) or attenuating Myc-induced UPR signaling (Perk−/−) disrupts c-Myc–associated ER stress, UPR activation, and autophagy in vivo and inhibits tumor growth.

To further test the role of PERK in Myc-induced transformation, we obtained hematopoietic progenitor cells (HPCs) from Perk−/− CreER mice, treatment of which with 4-HT induces Cre recombination activity resulting in PERK excision (Supplemental Figure 5I). Transformation of these cells with viruses overexpressing myc-GFP and dominant-negative p53 results in colony formation in methycellulose (Figure 5F) with minimal apoptosis, as measured by Annexin V–PE/7-AAD staining (Figure 5G). PERK excision via
Discussion

The role of the PERK pathway in tumor suppression is not completely understood, but there is strong evidence that Ca²⁺ release from ER stores induces cytochrome c release from the mitochondria (57, 58). This leads to the subsequent activation of caspase-3, -4, and -7 in human cells and of caspase-12 in rodents, which mediate apoptosis (59, 60). In our studies, we observed a significant increase in Ca²⁺ release from Perk⁻/⁻ cells following Myc upregulation, and importantly, the calcium chelator BAPTA-AM rescued a significant portion of Myc-induced apoptosis in these MEFs. The Ca²⁺ release was not as acute as that observed following treatment with the SERCA inhibitor thapsigargin, and this likely reflects the fact that the effect is more gradual, as misfolded proteins accumulate in the ER. The incomplete rescue achieved by calcium chelation suggests that additional mechanisms are contributing to cytotoxicity by c-Myc in the absence of PERK.

Antiapoptotic role of the PERK pathway: induction of autophagy and regulation of ER calcium release. If the UPR is activated by c-Myc, what is its role in the context of transformation by Myc? Is it now well established that activation of the UPR can have both pro-survival and pro-cell death consequences, depending on the cellular context, severity of stress, etc. Induction of ER stress–dependent apoptosis occurs after prolonged and/or severe ER stress caused by treatment with cytotoxic agents (54, 55). Conversely, due to their inability to downregulate protein synthesis, cells with a compromised UPR, such as those with abrogated PERK/ elf2α or Ire1/XBP1 signaling, are substantially more sensitive to ER-induced cell death than wild-type cells, presumably due to the continuous accumulation of misfolded proteins in the ER, a process termed proteotoxicity (54, 56). The mechanisms for ER stress–dependent apoptosis are not completely understood, but there is strong evidence that Ca²⁺ release from ER stores induces cytochrome c release from the mitochondria (57, 58). This leads to the subsequent activation of caspase-3, -4, and -7 in human cells and of caspase-12 in rodents, which mediate apoptosis (59, 60). In our studies, we observed a significant increase in Ca²⁺ release from Perk⁻/⁻ cells following Myc upregulation, and importantly, the calcium chelator BAPTA-AM rescued a significant portion of Myc-induced apoptosis in these MEFs. The Ca²⁺ release was not as acute as that observed following treatment with the SERCA inhibitor thapsigargin, and this likely reflects the fact that the effect is more gradual, as misfolded proteins accumulate in the ER. The incomplete rescue achieved by calcium chelation suggests that additional mechanisms are contributing to cytotoxicity by c-Myc in the absence of PERK.
Autophagy is another cytoprotective process that has been linked to activation of the UPR and particularly the PERK/EIF2α pathway (a process termed ER-phagy) (42). However, it has also been postulated that under certain physiological conditions and in response to specific treatments, autophagy leads to enhanced clonogenic cell death (17, 61). Sustained autophagy without a balancing synthesis of new materials would result in detrimental self-cannibalism beyond the possibility of cellular recovery. Previous work in yeast and mammalian cells has established that ER stress can activate autophagy. Rzemyński et al. have also reported that tumor hypoxia can enhance autophagic flux and thereby promote resistance to hypoxia-induced apoptosis both in vitro and in vivo (10, 62). It has been proposed that stressors such as nutrient deprivation result in the dissociation of Beclin 1 from Bcl-2, thereby countering apoptotic mechanisms, and that, importantly, the inhibition of autophagy makes cells more susceptible to stress-induced apoptosis (63). Indeed, our results show that PERK-mediated processing of LC3 and downregulation of p62, both markers of autophagy, occur following Myc activation. Interestingly, Maclean et al. have reported that in the Eμ-myc mouse model, an inhibitor of autophagic flux, chloroquine, increased clonogenic death of Myc-dependent lymphoma cells and impaired lymphoma development in a Burkitt’s lymphoma model, pointing toward a cytoprotective role of autophagy under c-Myc activation (19, 64). Moreover, we found evidence of LC3 processing in B cells from Eμ-myc mice but not from wild-type or double transgenic Eμ-myc/+;L24+/– mice, indicating that relieving ER stress by downregulating of protein load also alleviates autophagic induction.

**Figure 7**
Model of the role of UPR activation in cytoprotection during Myc-dependent transformation. c-Myc activation increases protein synthesis, resulting in UPR activation. This is attenuated by genetically reducing protein synthesis (L24 mouse minute) or pharmacologically increasing chaperone activity (4-PBA). In the presence of PERK, cytoprotective autophagy (LC3 processing, p62 degradation) is induced and is required for cell survival (ULK1 and Atg5 dependence). Loss of PERK results in significantly increased apoptosis, primarily through an increase Ca2+ release form the ER and lack of autophagy.

A link between Myc-induced translation, UPR activation, and transformation. It has been established that Myc-induced transformation requires the cooperation of pro-survival pathways for full transformation and tumorigenesis. It is likely that multiple such pathways with antiapoptotic activity may contribute to eventual transformation by Myc. Recently, one of our groups showed that protein synthesis is required for Myc-dependent tumorigenesis and optimal lymphoma progression (32). Importantly, this study demonstrated that restoration of Myc-induced protein synthesis rates to wild-type levels led to an increase in apoptosis and reduced lymphomagenesis, thereby uncovering a link between translational control by Myc and cell survival. Here, we show that one of the mechanisms by which Myc-overexpressing cells attain a survival advantage is protein synthesis–dependent activation of the UPR (Figure 7). Indeed, we demonstrate the mechanistic link between Myc-driven increases in protein synthesis and UPR activation both pharmacologically and genetically (Figure 5). The absence of PERK and eIF2α phosphorylation in Myc-overexpressing MEFs, and the absence of PERK from Myc-overexpressing bone marrow hematopoietic progenitor cells results in massive apoptosis and reduced clonogenicity (MEFs and HPCs) and reduced tumor growth (MEFs) when Myc is hyperactivated. Therefore, we have identified PERK as a sensor of the translational status of the cell and regulator of cell survival in the context of Myc hyperactivation. Our findings support the use of PERK inhibitors as an approach to target tumors driven by oncogenic Myc.

Collectively, our findings support a model (Figure 7) in which activation of autophagy in a PERK-dependent manner and amelioration of Ca2+ release by PERK contribute to increased resistance of transformed cells to c-Myc upregulation and increased ER load. Oncogenic activation of the UPR downstream of MYC amplification provides one possible escape mechanism for oncogene-induced stress that is required for cellular transformation and highlights a novel means of treating malignancies characterized by MYC translocations and amplifications.

**Methods**

**Cell lines, plasmids, and chemicals**
Cell lines were maintained in DMEM (Perkfl/fl and Perk−/− MEFS, Atg5+/+ and Atg5−/− MEFS) or RPMI-1640 (P493-6, SHEP N-MycER, and SHEP Tet-21) supplemented with 10% fetal bovine serum and penicillin/streptomycin and cultured in 5% CO2 at 37°C. Cell lines were provided by D. Cavener (Penn State University, State College, Pennsylvania, USA) (Perkfl/fl and Perk−/− MEFS), D. Eick (Center of Integrated Protein Science [CIPSM], Helmholtz Center Munich, Munich, Germany) (P493-6) (66), C. Beltinger (University Children’s Hospital, Ulm, Germany) (N-MycER SHEP) (36), J. Shohet (Baylor College of Medicine, Houston, Texas, USA) and M. Schwab (German Cancer Research Center, University of Heidelberg, Heidelberg, Germany) (SHEP Tet-21) (37), and C. Thompson and T. Lindsten (Memorial Sloan-Kettering Cancer Center, New York, New York, USA) (Atg5+/+ and Atg5−/− MEFS) (67). The MEFs were infected with retroviruses expressing either the mycER construct or control empty vector (mig), and stable clones were selected with puromycin. PERK was excised from the MEFs using an adenovirus expressing Cre recombinase, and clones were screened for loss of PERK. mycER activation was performed by treatment with 4-HT at 250 nM (vehicle was ethanol). The following reagents were used (purchased from Sigma-Aldrich unless otherwise noted): 4-HT, tamoxifen, tetracycline, thapsigargin, tunicamycin, staurosporine (MP Biomedicals), 4-PBA (Calbiochem), Q-VD-OPH (BioVision), BAPTA-AM, E64d, pepstatin A, bafilomycin A1, and Spautin-1 (Cellagen Technology).
**Immunoblotting**

Protein was harvested from cell lines as previously described (68). Immunoblotting was performed on extracts as previously described (68), with the exception that proteins were transferred to polyvinylidene fluoride membranes. See Supplemental Methods for details about the specific antibodies used.

**Flow cytometry and immunofluorescence**

ER-Tracker and Lysotracker studies. P493-6 cells were treated, collected, and resuspended (1 × 10^6 cells/ml) in complete RPMI-1640 medium. ER-Tracker (500 nM for 30 minutes) and Lysotracker (100 nM for 45 minutes) dyes (Invitrogen) were added to the resuspended cells in individual reactions at 37°C. Cells were then pelleted, resuspended in HBSS, and analyzed on a BD LSR II (BD Biosciences) flow cytometer at the University of Pennsylvania Flow Cytometry and Cell Sorting facility. Fluorophores were excited with a green 532-nm laser, and emission was captured with a 575/25 BP (Lysotracker) or a 610/20BP (ER-Tracker) and 600LP dichroic. Cell size was assessed based on forward scatter analysis. A similar ER-Tracker incubation was performed on attached cells for immunofluorescence images was assessed based on forward scatter analysis. A similar ER-Tracker incubation was performed on attached cells for immunofluorescence images of ER. Counterstaining was performed with DAPI. Fluorescence intensity was measured using a blank measurement from the mean fluorescence of each cell. Densitometric volumes were then determined by multiplying area by intensity, for 8 control (EtOH-treated) cells and 8 Myc-induced (4-HT–treated) cells.

**Bone marrow transformation studies**

Constructs and retroviruses. MSCV-myc-IRES-GFP has been reported elsewhere (70). DNp53 was subcloned into the BglIII/EcoRI-digested MSCV-IRES-NGFR vector (gift from Warren Pear, University of Pennsylvania). Retrovirus was produced with the constructs above by individually cotransfecting them with Pcl-Eco retrovirus packaging vector into 293T cells using Lipofectamine reagent (Invitrogen). Retroviral supernatant was harvested 48 and 72 hours after transfection, filtered, and stored at −80°C. The titer of the infectious virus was determined by flow cytometry using NIH 3T3 cells infected with serial dilutions of virus in the presence of 8 μg/ml Polybrene.

**Transformation assay.** Bone marrow cells from Perk^+/CreER mice treated with 5-FU (150 mg/kg) were retrovirally transduced (in the presence of IL-3, IL-6, and SCF) with myc-GFP, DNp53-NGFR, or the vector controls as indicated. GFP/NGFR double-positive cells were sorted and replated weekly in methylcellulose medium with 4-HT or ethanol vehicle. Colony numbers were counted after each replating, and colonies with >50 cells were scored and assessed for 3 rounds of serial replating.

**Bone marrow apoptosis studies.** Bone marrow cells were treated with 4-HT or vehicle for 4 days, transduced with the retroviruses as already described, and lysed with ACK buffer (BioWhittaker) and stained with APC-NGFR (BD Biosciences) 30 hours after transduction. The stained cells were further stained with Annexin V–PE/7-AAD according to the manufacturer’s instructions (BD Biosciences).

**MEF tumor growth studies**

MEFs (1 × 10^6 cells) were injected subcutaneously in the flanks of athymic nude mice (Taconic) with a total of 10 tumors per group (n = 10). For tamoxifen treatment, the hormone powder (Sigma-Aldrich) was dissolved by sonication in peanut oil (10 mg/ml), and mice were injected every 2 days (i.p.) at the dose of 1 mg per mouse. Tumor growth was measured with calipers. Tumor volume was calculated with the following equation: volume = 0.5(length × width²).

**Primary B cell isolation.** Eμ-myc/−, Eμ-myc/−;L24−/−, and WT mice were sacrificed at 5 weeks of age, and the spleens were harvested. Splenic B cells were purified by using a B cell isolation kit (Miltenyi Biotec 130-090-862) in conjunction with an AutoMACS cell sorter per the manufacturer’s protocol. Cell pellets were snap frozen in liquid nitrogen prior to RIPA lysis and immunoblot analysis, as previously described (32).

**Human tumor samples**

All human samples were obtained from patients presenting with acute myeloid leukemia. They were provided by the Stem Cell and Xenograft Core Facility at the University of Pennsylvania School of Medicine. Leukapheresis samples were frozen in fetal calf serum with 10% DMSO and stored in liquid nitrogen. French-American-British (FAB) or WHO classification and cytogenetics in AML samples were determined at the time of diagnosis by the Laboratory of Pathology and Medicine at the Hospital of the University of Pennsylvania. Protein and RNA from 7 malignant samples and 2 samples obtained from normal donors were harvested for immunoblot and qPCR analysis, as described in the Supplemental Methods.

**Statistics**

Where necessary, data were statistically analyzed to generate standard error values and determine the level of significance using the Student’s t test (1-tailed or 2-tailed tests are denoted in the corresponding figure legends). Where appropriate, P-values are provided in the legends. Data represent mean values ± SEM.
Study approval

For human tissues, informed consent was obtained under a protocol reviewed and approved by the Institutional Review Board at the University of Pennsylvania (IRB protocol 703185). All animal experiments were approved by and performed according to University of Pennsylvania and UCSF IACUC regulations.

Acknowledgments

We thank Douglas Cavener for providing Perk KO mice for the isolation of the MEFs and Craig Thompson and Tullia Lindsten for sharing the Atp5 γ−/− and Atp5 γ−/− MEFs. We also thank Carly Sayers for critical reading of the manuscript and Michael Dews and Elena Sotillo-Pineiro for technical guidance. D. Ruggero is a Leukemia and Lymphoma Society Scholar. This work is supported by NIH R01CA094214 and NIH R01CA139362 (to C. Koumenis); ACS 121364-PF-11-184-01-TBG (to J.T. Cunningham); NIH R01CA140456 (to D. Ruggero); R01CA122334 (to A. Thomas-Tikhonenko); and by Commonwealth of Pennsylvania Universal Research Enhancement Program Funds and P01CA104838 to J. Alan Diehl.

Address for publication received on February 19, 2012, and accepted in revised form September 6, 2012.

Received for publication on November 19, 2012, and accepted in revised form September 6, 2012.

Lori S. Hart’s present address is: Division of Oncology and Center for Childhood Cancer Research, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.